Innovent Biologics Inc. has announced the commencement of the first participant dosing in their GLORY-3 Phase 3 clinical study in China. This study focuses on evaluating the efficacy and safety of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide 1 receptor (GLP-1) receptor agonist, compared to semaglutide in adults with overweight or obesity accompanied by metabolic dysfunction-associated fatty liver disease (MAFLD). The trial aims to enroll approximately 470 participants, assessing primary endpoints such as changes in liver fat content and body weight over 48 weeks. Innovent's Senior Vice President of Clinical Development, Dr. Lei Qian, expressed confidence in mazdutide's potential to provide comprehensive metabolic benefits and a better treatment option for Chinese patients struggling with obesity-related MAFLD.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.